17.24  0.01 (0.06%)		05-06 16:00
Open: 17.24 High: 17.628 Volume: 25,107		Pre. Close: 17.23 Low: 16.925 Market Cap: 577(M)

Short term
Mid term
Targets	6-month :	22.16	1-year :	25.89
Resists	First :	18.97	Second :	22.16
Pivot price	16.17
Supports	First :	16.11	Second :	14.35
MAs	MA(5) :	16.89	MA(20) :	16.43
	MA(100) :	0	MA(250) :	0
MACD	MACD :	-0.4	Signal :	-0.6
%K %D	K(14,3) :	82.7	D(3) :	74.2
RSI	RSI(14): 53.2
52-week	High :	23.12	Low :	14.35

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ AVBP ] has closed below upper band by 8.9%. Bollinger Bands are 0% narrower than normal.

If tomorrow:	Open lower	Open higher
High:	17.64 - 17.69	17.69 - 17.75
Low:	16.77 - 16.83	16.83 - 16.9
Close:	17.13 - 17.22	17.22 - 17.33

ArriVent BioPharma, Inc. operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. It also engages in the development and commercialization of targeted cancer therapies for non-small-cell lung cancer (NSCLC) and other solid tumors. The company develops Furmonertinib, an epidermal growth factor receptor mutant-selective tyrosine kinase inhibitor that is in phase 3 clinical trial for the treatment of NSCLC patients; and ARR-002. It has strategic collaborations with Aarvik Therapeutics Inc. The company was incorporated in 2021 and is based in Newtown Square, Pennsylvania.

Sat, 04 May 2024
ArriVent BioPharma (NASDAQ:AVBP) Earns Buy Rating from Analysts at HC Wainwright - Defense World

Thu, 02 May 2024
HC Wainwright Comments on ArriVent BioPharma, Inc.'s Q1 2024 Earnings (NASDAQ:AVBP) - MarketBeat

Fri, 26 Apr 2024
ArriVent BioPharma (NASDAQ:AVBP) Trading Up 6% - MarketBeat

Wed, 17 Apr 2024
ArriVent BioPharma (NASDAQ:AVBP) Stock Price Down 3.3% - MarketBeat

Sun, 04 Feb 2024
StockWatch: Alto, Fractyl, FibroBiologics Join Parade of Public Biotechs - Genetic Engineering & Biotechnology News

Sun, 28 Jan 2024
StockWatch: IPO Revival? CG Oncology, ArriVent Raise a Combined $555M - Genetic Engineering & Biotechnology News

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Neutral
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Neutral
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Neutral
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Neutral
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Neutral
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Neutral

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	33 (M)
Shares Float	18 (M)
Held by Insiders	13.6 (%)
Held by Institutions	42.2 (%)
Shares Short	945 (K)
Shares Short P.Month	95 (K)

EPS	0
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	0
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	-27 %
Return on Equity (ttm)	-42.6 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	0
Qtrly Earnings Growth	0 %
Operating Cash Flow	-56 (M)
Levered Free Cash Flow	-33 (M)

PE Ratio	0
PEG Ratio	0
Price to Book value	0
Price to Sales	0
Price to Cash Flow	-10.34

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.